{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:01:36Z","timestamp":1784955696198,"version":"3.55.0"},"reference-count":31,"publisher":"The Japanese Society for Neuroendovascular Therapy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NOUSHINKEI KEKKANNAI TIRYOU","JNET"],"published-print":{"date-parts":[[2026]]},"DOI":"10.5797\/jnet.ra.2025-0166","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:11:40Z","timestamp":1784931100000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy after Structural Heart Disease Intervention"],"prefix":"10.5797","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-4663","authenticated-orcid":false,"given":"Hidehiko","family":"Hara","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3804","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Brouwer J, Nijenhuis V, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. <i>N Engl J Med<\/i> 2020; 383: 1447\u20131457.","DOI":"10.1056\/NEJMoa2017815"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. <i>N Engl J Med<\/i> 2010; 363: 1597\u20131607.","DOI":"10.1056\/NEJMoa1008232"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>Eur Heart J<\/i> 2022; 43: 561\u2013632.","DOI":"10.1093\/eurheartj\/ehac051"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Dangas GD, Tijssen J, Wohrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. <i>N Engl J Med<\/i> 2020; 382: 120\u2013129.","DOI":"10.1056\/NEJMoa1911425"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation. <i>N Engl J Med<\/i> 2020; 382: 1696\u20131707.","DOI":"10.1056\/NEJMoa1915152"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. <i>Eur Heart J<\/i> 2022; 43: 2783\u20132797.","DOI":"10.1093\/eurheartj\/ehac408"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Rashid HN, Brown AJ, McCormick LM, et al. Subclinical leaflet thrombosis in transcatheter aortic valve replacement detected by multidetector computed tomography \u2015a review of current evidence\u2015. <i>Circ J<\/i> 2018; 82: 1735\u20131742.","DOI":"10.1253\/circj.CJ-17-1363"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Makkar RR, Blanke P, Leipsic J, et al. Subclinical leaflet thrombosis in transcatheter and surgical bioprosthetic valves: PARTNER 3 cardiac computed tomography substudy. <i>J Am Coll Cardiol<\/i> 2020; 75: 3003\u20133015.","DOI":"10.1016\/j.jacc.2020.04.043"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Ahmad S, Albaeni A, Salehin S, et al. Effect of periprocedural anticoagulation on patient outcomes after transcatheter edge to edge repair of mitral valve with MitraClip<sup>TM<\/sup>; an insight from nationwide dataset. <i>Int J Cardiol Heart Vasc<\/i> 2025; 57: 101644.","DOI":"10.1016\/j.ijcha.2025.101644"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Euper M, Schreieck J, Bladt M, et al. Dynamics of thrombogenicity and platelet function and correlation with bleeding risk in patients undergoing M-TEER using the PASCAL system. <i>Thromb Haemost<\/i> 2025; 125: 130\u2013141.","DOI":"10.1055\/s-0044-1790604"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Claeys MJ, Aminian A, Bartunek J, et al. Bleeding and thrombotic risk of different antiplatelet regimens posttranscatheter edge-to-edge mitral valve repair in patients with an indication for oral anticoagulation: results from an all-comers national registry. <i>Catheter Cardiovasc Interv<\/i> 2024; 103: 382\u2013388.","DOI":"10.1002\/ccd.30931"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Waechter C, Ausbuettel F, Chatzis G, et al. Antithrombotic treatment and its association with outcome in a multicenter cohort of transcatheter edge-to-edge mitral valve repair patients. <i>J Cardiovasc Dev Dis<\/i> 2022; 9: 366.","DOI":"10.3390\/jcdd9110366"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Pamporis K, Tsiachris D, Grigoriou K, et al. One-stop mitral valve transcatheter edge-to-edge repair and left atrial appendage occlusion in patients with atrial fibrillation and mitral regurgitation: a systematic review and meta-analysis. <i>J Pers Med<\/i> 2025; 15: 197.","DOI":"10.3390\/jpm15050197"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hammad A, Ahmad A, Khraisat O, et al. Patent foramen ovale closure vs medical therapy in secondary prevention of stroke and TIA: a systematic review and meta-analysis. <i>Cardiovasc Revasc Med<\/i> 2026; 85: 1\u20139.","DOI":"10.1016\/j.carrev.2025.06.037"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. <i>N Engl J Med<\/i> 2017; 377: 1022\u20131032.","DOI":"10.1056\/NEJMoa1610057"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) S\u00f8ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. <i>N Engl J Med<\/i> 2017; 377: 1033\u20131042.","DOI":"10.1056\/NEJMoa1707404"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Guedeney P, Farjat-Pasos J, Asslo G, et al. Impact of the antiplatelet strategy following patent foramen ovale percutaneous closure. <i>Eur Heart J Cardiovasc Pharmacother<\/i> 2023; 9: 601\u2013607.","DOI":"10.1093\/ehjcvp\/pvad023"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Akagi T, Hara H, Kanazawa H, et al. Real-world patent foramen ovale closure in Japan \u2015results from 1-year follow-up of the Amplatzer<sup>TM<\/sup> PFO Occluder Japan Post-Marketing Surveillance study\u2015. <i>Circ J<\/i> 2025; 90: 109\u2013117.","DOI":"10.1253\/circj.CJ-25-0115"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Apostolos A, Papanikolaou A, Drakopoulou M, et al. Safety and efficacy of antiplatelet cessation after transcatheter patent foramen ovale closure. <i>Eur J Prev Cardiol<\/i> 2024; 31(Suppl 1): wae175.188.","DOI":"10.1093\/eurjpc\/zwae175.188"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Wallenborn J, Bertog SC, Franke J, et al. Recurrent events after percutaneous closure of patent foramen ovale. <i>Catheter Cardiovasc Interv<\/i> 2013; 82: 541\u2013546.","DOI":"10.1002\/ccd.24511"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Hardt SE, Eicken A, Berger F, et al. Closure of patent foramen ovale defects using GORE\u00ae CARDIOFORM septal occluder: results from a prospective European multicenter study. <i>Catheter Cardiovasc Interv<\/i> 2017; 90: 824\u2013829.","DOI":"10.1002\/ccd.26993"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. <i>JAMA<\/i> 2014; 312: 1988\u20131998.","DOI":"10.1001\/jama.2014.15192"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Reddy VY, Doshi SK, Kar S, et al. 5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. <i>J Am Coll Cardiol<\/i> 2017; 70: 2964\u20132975.","DOI":"10.1016\/j.jacc.2017.10.021"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Bergmann MW, Betts TR, Sievert H, et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. <i>EuroIntervention<\/i> 2017; 13: 877\u2013884.","DOI":"10.4244\/EIJ-D-17-00042"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. <i>Circulation<\/i> 2021; 143: 1754\u20131762.","DOI":"10.1161\/CIRCULATIONAHA.120.050117"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Kondo Y, Ryuzaki S, Nakano M, et al. Left atrial appendage closure: current status, unresolved issues, and future perspectives. <i>Cardiovasc Interv Ther<\/i> 2026; 41: 292\u2013304.","DOI":"10.1007\/s12928-025-01222-6"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Coylewright M, Holmes DR Jr., Kapadia SR, et al. DAPT is comparable to OAC following LAAC with WATCHMAN FLX: a national registry analysis. <i>JACC Cardiovasc Interv<\/i> 2023; 16: 2708\u20132718.","DOI":"10.1016\/j.jcin.2023.08.013"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lakkireddy D, Ellis CR, Thaler D, et al. 5-Year results from the AMPLATZER Amulet left atrial appendage occluder randomized controlled trial. <i>J Am Coll Cardiol<\/i> 2025; 85: 1141\u20131153.","DOI":"10.1016\/j.jacc.2024.10.101"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hara H, Kubo S, Nakajima Y, et al. Initial results of transcatheter modification of left atrial appendage by obliteration with device in patients with nonvalvular atrial fibrillation: real-world data from the TERMINATOR registry. <i>J Cardiol<\/i> 2024; 83: 298\u2013305.","DOI":"10.1016\/j.jjcc.2023.09.010"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Kar S, Doshi SK, Alkhouli M, et al. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation. <i>Am Heart J<\/i> 2023; 264: 123\u2013132.","DOI":"10.1016\/j.ahj.2023.05.022"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Saw J, Nielsen-Kudsk JE, Bergmann M, et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. <i>JACC Cardiovasc Interv<\/i> 2019; 12: 1067\u20131076.","DOI":"10.1016\/j.jcin.2018.11.001"}],"container-title":["Journal of Neuroendovascular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnet\/20\/1\/20_ra.2025-0166\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:17:01Z","timestamp":1784953021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jnet\/20\/1\/20_ra.2025-0166\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5797\/jnet.ra.2025-0166","relation":{},"ISSN":["1882-4072","2186-2494"],"issn-type":[{"value":"1882-4072","type":"print"},{"value":"2186-2494","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"ra.2025-0166"}}